Group 1 - Dazhihui reported that its daily operations are normal and there are no significant changes [4] - Jinchengzi announced that revenue from laser 3D printing control systems will account for less than 2% of total revenue in 2024 [5][6] - Bayi Shikong is expanding into edge computing business [8] - Zhengfan Technology plans to acquire 62.23% stake in Hanjing Semiconductor [10] - Dayang Electric is planning to issue H-shares and list on the Hong Kong Stock Exchange [18] Group 2 - Haitong Development intends to use up to $65 million to purchase dry bulk carriers [2] - Juhua Co. expects a net profit of 1.97 billion to 2.13 billion yuan for the first half of 2025, a year-on-year increase of 136% to 155% [3] - Dajin Heavy Industry anticipates a net profit of 510 million to 570 million yuan for the first half of 2025, a year-on-year increase of 193.32% to 227.83% [11] - Yatai Co. expects a net profit of 190 million to 210 million yuan for the first half of 2025, a year-on-year increase of 81.97% to 101.13% [12] - Huizhong Co. expects a net profit of 39.98 million to 42.03 million yuan for the first half of 2025, a year-on-year increase of 95% to 105% [13]

[Performance Forecast Overview](index=1&type=section&id=Item%20I.%20Current%20Period%20Performance%20Forecast) The company forecasts strong year-over-year growth for H1 2025, with operating revenue up 45%-55% and net profit attributable to shareholders up 95%-105% Key Financial Performance Indicators | Item | Current Reporting Period (Jan 1 – Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Operating Revenue** | CNY 203.9982 million – CNY 218.0670 million | CNY 140.6884 million | | Year-over-Year Growth | 45% - 55% | - | | **Net Profit Attributable to Shareholders of Listed Company** | CNY 39.9762 million – CNY 42.0262 million | CNY 20.5006 million | | Year-over-Year Growth | 95% - 105% | - | | **Net Profit Excluding Non-Recurring Gains and Losses** | CNY 35.1409 million – CNY 36.7754 million | CNY 16.3446 million | | Year-over-Year Growth | 115% - 125% | - | [Pre-Audit Status](index=1&type=section&id=Item%20II.%20Pre-Audit%20Status%20of%20Performance%20Forecast) The financial data in this performance forecast represents preliminary calculations by the company's finance department and remains unaudited by a certified public accountant - The financial data in this performance forecast has not been audited by a certified public accountant[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=Item%20III.%20Explanation%20of%20Performance%20Changes) The company's H1 2025 performance growth is primarily driven by increased overseas sales and a positive contribution from non-recurring gains and losses - The year-over-year growth in operating revenue and net profit is primarily attributed to increased sales in overseas markets[4](index=4&type=chunk) - Non-recurring gains and losses are expected to contribute approximately **CNY 5.20 million** to net profit during the reporting period[5](index=5&type=chunk) [Other Notes and Risk Warning](index=2&type=section&id=Item%20IV.%20Other%20Related%20Notes) The company states this performance forecast is preliminary and unaudited, with final financial data to be disclosed in the 2025 semi-annual report, urging investors to exercise caution - This performance forecast represents preliminary calculations by the company's finance department and has not been audited, with final financial data subject to the 2025 semi-annual report[6](index=6&type=chunk) - The company advises investors to exercise caution in their decisions and be aware of investment risks[6](index=6&type=chunk)

Group 1 - The company Huizhong Co., Ltd. (stock code: 300371) announced an expected revenue of 204 million to 218 million yuan for the period from January 1, 2025, to June 30, 2025, representing a growth of 45% to 55% compared to the same period last year, which was 141 million yuan [1] - The net profit attributable to shareholders of the listed company is expected to be between 39.9762 million and 42.0262 million yuan, an increase of 95% to 105% compared to the same period last year, which was 20.5006 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 35.1409 million and 36.7754 million yuan, reflecting a growth of 115% to 125% compared to the same period last year, which was 16.3446 million yuan [1]

Core Viewpoint - The company has approved the use of idle funds to purchase financial products to enhance short-term capital efficiency and increase returns, with a total limit of 600 million yuan for the year [1]. Group 1: Approval and Investment Limits - The company held board and supervisory meetings to approve the use of idle funds for financial product investments, with a maximum investment limit of 600 million yuan [1]. - Individual investment in any financial product is capped at 100 million yuan, with investment periods not exceeding twelve months [1]. Group 2: Progress of Financial Product Investments - The company has made several investments in structured deposits with various banks, including: - 15 million yuan with China Merchants Bank, expected annual return of 1.5%-2.00%, maturing on December 25, 2025 [2]. - 28 million yuan with CITIC Bank, expected annual return of 1.05%-2.07%, maturing on August 13, 2025 [2]. - Additional investments include amounts of 25 million yuan, 30 million yuan, and 20 million yuan with similar expected returns and maturity dates [2]. Group 3: Impact on Daily Operations - The investment in low-risk financial products is designed to ensure that daily operations and capital safety are maintained, without affecting the company's cash flow needs [4]. - The expected returns from these investments are anticipated to enhance the overall performance of the company and safeguard shareholder interests [4]. Group 4: Historical Investment Overview - In the past twelve months, the company and its subsidiaries have engaged in various financial product investments, with amounts ranging from 15 million yuan to 4 million yuan, all yielding positive returns [4][5][6]. - The historical investments include structured deposits with expected annual returns between 1.05% and 2.35% [4][5][6].

代码：300371 证券简称：汇中股份 公告编号：2025-056 汇中仪表股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、购买理财产品审批情况 汇中仪表股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开了第五 届董事会第十八次会议、第五届监事会第十三次会议，2025 年 5 月 16 日召开 2024 年年度股东大会审议通过了《关于使用自有闲置资金购买理财产品的议案》。为 提高资金短期使用效率，增加公司收益，根据公司资金使用情况，在不影响公司 正常经营所需流动资金的情况下，同意公司使用全年累计额度不超过 60,000 万 元的自有闲置资金购买理财产品，其中单个理财产品的投资额度不超过 10,000 万元。期限自 2024 年年度股东大会审议通过之日起至 2025 年年度股东大会召开 之日止，单个理财产品的投资期限不超过十二个月，同时授权公司董事长在该额 度范围内行使投资决策权，并签署相关法律文件。详见公司 2025 年 4 月 18 日于 中国证监会指定网站巨潮资讯网（www. ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：300371 证券简称：汇中股份 公告编号：2025-055 汇中仪表股份有限公司 关于与 Almaviva Bluebit 公司签署战略合作协议的 自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次签订的战略合作协议仅为框架性、意向性约定，旨在表达双方合作 意向，确定双方互为战略合作伙伴关系。后续合作与具体业务推进等事项尚需 双方进一步协商确定，具体合作内容以签订的具体协议为准，具体实施情况存 在不确定性。 一、基本情况概述 汇中仪表股份有限公司（以下简称"汇中股份"或"公司"）与 Almaviva Bluebit S.P.A. Societa 'Benefit（以下简称：Almaviva Bluebit 公司）于近日签订 了《战略合作协议》（以下简称"协议""本协议"），双方将在意大利建立独 家合作伙伴关系，并以开拓全球超声水表市场为目标，加强交流与协作，共创 发展契机。合作内容包括但不限于深化产业合作、加强研发协同、改善供应链 管理、新产品市场开拓等。 二、协议签订的基本情况 甲方：汇中仪表股份有限公司 乙 ...

Core Viewpoint - The company has signed a strategic cooperation agreement with Almaviva Bluebit to establish an exclusive partnership in Italy, aiming to expand the global ultrasonic water meter market [1] Group 1: Strategic Cooperation - The cooperation will focus on deepening industrial collaboration, enhancing research and development synergy, improving supply chain management, and exploring new product markets [1] - This strategic partnership is expected to positively impact the company's brand and ultrasonic flow measurement products, gaining recognition from overseas market customers [1] Group 2: Market Impact - The collaboration is anticipated to create long-term and stable sales in the overseas market for the company [1]

证券代码：300371 证券简称：汇中股份 公告编号：2025-054 汇中仪表股份有限公司 中长期员工持股计划（第一期）第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 中长期员工持股计划（第一期）第一次持有人会议于 2025 年 6 月 13 日在本 公司会议室以现场方式召开。 本次会议应出席持有人 118 人，实际出席 60 人，代表员工持股计划份额 6,556,253.85 份，占公司中长期员工持股计划（第一期）总持有人的 70.61%。会 议由董事会秘书李俊杰先生主持，本次会议符合公司中长期员工持股计划（第一 期）的相关规定，会议的召集、召开合法有效。 表决结果：同意 6,556,253.85 份，占出席持有人会议的持有人所持份额总数 的 100%，反对 0 份，弃权 0 份。 3、《关于授权汇中仪表股份有限公司中长期员工持股计划（第一期）管理 委员会办理本次员工持股计划相关事宜的议案》； 为保证公司中长期员工持股计划（第一期）事宜的顺利进行，拟提请员工持 股计划持有人会议授权管理委员会办理员工持股计划的相关 ...

证券代码：300371 证券简称：汇中股份 公告编号：2025-053 汇中仪表股份有限公司 关于董事会完成换届选举暨选举董事长、董事会各专门委员会 委员及聘任高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 汇中仪表股份有限公司（以下简称"公司"）于 2025 年 6 月 9 日召开了 2025 年第三次临时股东大会，选举产生了第六届董事会 5 名非独立董事、3 名独立董 事与公司职工代表大会选举产生的 1 名职工代表董事，共同组成新一届董事会。 同日公司召开第六届董事会第一次会议、选举产生了董事长、董事会各专门 委员会委员，聘任了第六届高级管理人员。现将具体事项公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 6 月 9 日公司召开 2025 年第三次临时股东大会，采用累积投票制的 方式选举张力新先生、冯大鹏先生、陈辉女士、郭立志先生、张继川先生担任公 司第六届董事会非独立董事，选举唐欣女士、王富强先生、吴凡女士为公司第六 届董事会独立董事。非独立董事、职工代表董事与独立董事共同组成公司第六届 董事会，任期自股东大会选 ...